Form 4: Gillian Cannon, Corcept Therapeutics Director, Reports Stock Option Grant

Director Gillian Cannon reports the acquisition of stock options in Corcept Therapeutics.

Summary

• Gillian Cannon, a director of Corcept Therapeutics, filed a Form 4 with the SEC.
• The filing reports the acquisition of 30,000 stock options on May 17, 2024, at an exercise price of $28.09.
• The options vest ratably over one year, beginning May 17, 2024, and expire on May 16, 2034.
• Cannon directly owns 30,000 derivative securities following the reported transaction.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing related to stock option grants, which is generally neutral in sentiment. It reflects standard executive compensation practices.

Positives

• The grant of stock options to a director aligns their interests with those of shareholders.

Industry Context

Stock option grants are a common form of executive compensation in the pharmaceutical industry, used to incentivize performance and align management interests with shareholder value.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors and executives in publicly traded companies, particularly in the biotech and pharmaceutical sectors.
• The vesting schedule of one year is fairly typical, although some companies may use longer vesting periods to encourage long-term commitment.
• The exercise price is set at the market price on the grant date, which is standard practice.

Stakeholder Impact

• The stock option grant could potentially incentivize the director to act in ways that increase shareholder value.

Key Dates